Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 61,493 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 61,493 shares of the firm’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $6.44, for a total transaction of $396,014.92. Following the completion of the sale, the insider owned 13,920,778 shares of the company’s stock, valued at $89,649,810.32. The trade was a 0.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Wednesday, November 26th, Endurance (Cayman) Ltd Svf sold 127,938 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.39, for a total transaction of $817,523.82.
• On Tuesday, November 25th, Endurance (Cayman) Ltd Svf sold 235,971 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.38, for a total transaction of $1,505,494.98.
• On Monday, November 24th, Endurance (Cayman) Ltd Svf sold 227,803 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.15, for a total value of $1,400,988.45.
• On Wednesday, October 29th, Endurance (Cayman) Ltd Svf sold 100 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.49, for a total value of $649.00.
• On Tuesday, October 28th, Endurance (Cayman) Ltd Svf sold 24,453 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.50, for a total value of $158,944.50.
• On Monday, October 27th, Endurance (Cayman) Ltd Svf sold 66,403 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total value of $401,738.15.
• On Friday, October 24th, Endurance (Cayman) Ltd Svf sold 46,696 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.96, for a total value of $278,308.16.
• On Thursday, October 23rd, Endurance (Cayman) Ltd Svf sold 154,383 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.99, for a total value of $924,754.17.
• On Wednesday, October 22nd, Endurance (Cayman) Ltd Svf sold 144,266 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.15, for a total transaction of $887,235.90.
• On Tuesday, October 21st, Endurance (Cayman) Ltd Svf sold 109,675 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.30, for a total transaction of $690,952.50.

Vir Biotechnology Price Performance

VIR opened at $6.07 on Tuesday. The firm has a 50 day simple moving average of $5.77 and a 200 day simple moving average of $5.32. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $14.45. The company has a market cap of $844.46 million, a price-to-earnings ratio of -1.68 and a beta of 1.34.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, November 5th. The company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $1.98 million. Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.Vir Biotechnology’s revenue was up .8% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.56) EPS. As a group, analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors have recently modified their holdings of VIR. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology in the 2nd quarter valued at approximately $35,000. Federated Hermes Inc. lifted its stake in Vir Biotechnology by 153.8% in the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after buying an additional 4,899 shares in the last quarter. Apollon Wealth Management LLC acquired a new position in shares of Vir Biotechnology in the second quarter valued at approximately $50,000. Daiwa Securities Group Inc. increased its position in shares of Vir Biotechnology by 2,200.6% during the second quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock worth $62,000 after acquiring an additional 11,773 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Vir Biotechnology during the second quarter worth $63,000. Institutional investors own 65.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on VIR shares. Bank of America upgraded Vir Biotechnology from a “neutral” rating to a “buy” rating and upped their price objective for the company from $12.00 to $14.00 in a report on Wednesday, August 27th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a research report on Monday, September 15th. Evercore ISI began coverage on shares of Vir Biotechnology in a research report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price target on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Vir Biotechnology in a report on Monday, November 24th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).